TTI — Thiogenesis Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$41.99m
- CA$34.71m
Annual balance sheet for Thiogenesis Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | — | 7.08 | 3.85 | 1.62 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | — | 0.085 | 0.088 | 0.077 |
| Prepaid Expenses | ||||
| Total Current Assets | — | 7.24 | 3.98 | 1.81 |
| Total Assets | — | 7.24 | 3.98 | 1.81 |
| Payable / Accrued | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | — | 1.71 | 0.558 | 1.24 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | — | 1.71 | 0.558 | 1.24 |
| Common Stock | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | — | 5.53 | 3.43 | 0.574 |
| Total Liabilities & Shareholders' Equity | — | 7.24 | 3.98 | 1.81 |
| Total Common Shares Outstanding |